Abbott announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data. This automated insulin delivery system, or AID, solution is now available in Germany and will be available in additional European countries beginning in 2023. Advanced diabetes technologies, such as AID systems, are designed to help people living with diabetes improve their glucose control and reduce the burden of daily diabetes management. Integrating CamDiab’s CamAPS FX mobile app and Ypsomed’s mylifeTM YpsoPump with accurate2, real-time data from Abbott’s FreeStyle Libre 3 sensor, the connected solution continuously monitors a person’s glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time, removing the guesswork of insulin dosing and helping people with diabetes reach better treatment targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott announces FDA approval of Eterna SCS system
- Abbott price target raised to $125 from $114 at Citi
- Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
- Abbott board increases quarterly dividend 8.5% to 51c per share
- Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity